ADXS Advaxis, Inc.

+0  (2%)
Previous Close 8.06
Open 8.10
Price To book 3.02
Market Cap 332.43M
Shares 40,295,000
Volume 391,573
Short Ratio 12.06
Av. Daily Volume 607,494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac
Cervical cancer
Phase 1/2 updated data due 2H 2017.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Announced Phase 3 first patient dosed - February 6, 2017.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac - GOG 0265 study
Cervical cancer
Phase 1b ongoing.
HER2-driven malignancies - cancer
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac
Anal cancer (FAWCETT)

Latest News

  1. ETFs with exposure to Advaxis, Inc. : April 21, 2017
  2. Advaxis Appoints Anthony Lombardo as Chief Business Officer
  3. ETFs with exposure to Advaxis, Inc. : March 27, 2017
  4. Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
  5. EMA Certification Paves Way for Advaxis Drug
  6. EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer
  7. Advaxis, Inc. :ADXS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017
  8. Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer
  9. Advaxis to Present at the 2017 Barclays Global Healthcare Conference
  10. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : March 10, 2017
  11. Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical
  12. Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug
  13. Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO
  14. These 5 Stocks Under $10 Could Explode Up Soon
  15. Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
  16. Advaxis Inks Cancer Drug Deal with Sellas
  17. Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
  18. Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
  19. GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer